Press Releases
Διεθνές συνέδριο στη Λευκωσία για τη βιοτεχνολογία, την καινοτομία στην υγεία και την πρόσβαση των ασθενών
Το συνέδριο διοργανώνει η ΚΕΦΕΑ σε συνεργασία με την EFPIA Λευκωσία, 30/4/2026 Η Κυπριακή Ένωση Φαρμακευτικών Εταιρειών Έρευνας και Ανάπτυξης (ΚΕΦΕΑ) σε συνεργασία με την Ευρωπαϊκή Ομοσπονδία Φαρμακευτικών Βιομηχανιών και Ενώσεων (EFPIA), διοργανώνει συνέδριο με τίτλο...
Σταθερά κάτω από τον ευρωπαϊκό μέσο όρο η Κύπρος στην πρόσβαση σε καινοτόμα φάρμακα και θεραπείες
Μόλις 63 φάρμακα από τα 173 εγκεκριμένα από τις ευρωπαϊκές Αρχές διατίθενται στην Κύπρο την περίοδο 2020-23 Λευκωσία, 8 Μαΐου 2025 Η θέση της Κύπρου στην πρόσβαση ασθενών σε καινοτόμα φάρμακα παραμένει χαμηλή μεταξύ των ευρωπαϊκών χωρών, σύμφωνα με τα ευρήματα της...
KEFEA ANNOUNCEMENT: White list of 5* hotels for events in Cyprus
29 January 2025 The Board of Directors of the Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) held a meeting on 29 January 2025 and decided as follows: With regard to section 19.9 of its Code of Conduct, KEFEA has made the decision to...
KEFEA ANNOUNCEMENT: White list of 5* hotels for events in Cyprus
The Board of Directors of the Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) held a meeting on 31 January 2024 and decided as follows: With regard to section 19.9 of its Code of Conduct, KEFEA has made the decision to renew its white...
KEFEA ANNOUNCEMENT: White list of 5* hotels for events in Cyprus
December 15, 2022 With regard to section 19.9 of its Code of Conduct, KEFEA has made the decision to establish a white list of 5* hotels in Cyprus, in which KEFEA members may hold and sponsor events, should they wish to do so. The white list was considered necessary...
KEFEA ANNOUNCEMENT: White list of 5* hotels for events in Cyprus
With regard to section 19.9 of its Code of Conduct, KEFEA has made the decision to establish a white list of 5* hotels in Cyprus, in which KEFEA members may hold and sponsor events, should they wish to do so. The white list was considered necessary due to the paucity...
KEFEA: Vote on NHS law is important
Paves the way to improve patients’ access to innovative medicines The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) welcomes the vote on the NHS bill by the House of Representatives Plenum. This is an important moment for the Republic...
Kyriakos Mikellis re-elected president of KEFEA
NHS and falsified medicines top priorities of new Board Kyriakos Mikellis, Cyprus Business Manager at Pfizer, has been re-elected president of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) for another two year term. In statements,...
Transparency in relations between pharmaceutical companies, health professionals and health organisations
KEFEA: Aim is to boost credibility at European level Transfers of value made by pharmaceutical companies involving the expenses incurred in relation to healthcare professionals and healthcare organisations are to be made public for the first time by the end of June as...
KEFEA statement on labelling of pharmaceutical products
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) is surprised by media reports claiming that 40% of pharmaceutical products at state pharmacies are inadequately labelled. In statements, KEFEA President Kyriacos Mikellis said that “as...